Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS12010 capsules in adults with moderate-to-severe atopic dermatitis
CTR20260530Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QLS12010 in atopic dermatitis (AD) (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Percent change from baseline in Eczema Area and Severity Index (EASI) at week 16. Started Apr 2026; status: active.
02
Drugs
QLS12010
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20260530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260530.